---
date: 2017-06-13
title: Summary of PKPD of biotech drugs chapter 12
categories: [medicine, english, pharmacology]
tags: [medicine, biothch-drug, pk, pd, new-drug-development]
banner: 'http://www.nature.com/nrd/journal/v9/n4/images/nrd3003-f1.jpg'
bibliography: 'bib/biotechch12.bib'
---

<!-- BLOGDOWN-HEAD -->
<!-- /BLOGDOWN-HEAD -->

<!-- BLOGDOWN-BODY-BEFORE -->
<!-- /BLOGDOWN-BODY-BEFORE -->
<p>This is a summary of the book chapter 12. <span class="citation">(Meibohm 2006)</span> <!--more--></p>
<div id="hormones" class="section level2">
<h2>Hormones</h2>
<ul>
<li>Homeostatic feedback systems</li>
<li>example: insulin, PTH, cytokines</li>
<li>insulin: stimulating glucose update into cells
<ul>
<li>half-life: 5-6</li>
<li>SC dosing - flip-flop kinetics: C<sub>max</sub>, T<sub>max</sub></li>
</ul></li>
<li>PTH
<ul>
<li>Teriparatide (N-terminal 34-mer of full-length PTH, approved)</li>
<li>Anabolic effect - stimulation of osteoblasts</li>
<li>PTH1R</li>
</ul></li>
</ul>
</div>
<div id="cytokine" class="section level2">
<h2>Cytokine</h2>
<ul>
<li>HGF - nonlinearity</li>
<li>Thrombopoietin analogue (PEG-rHuMGDF) - Modeling of thrombopoietic effects</li>
</ul>
</div>
<div id="soluble-receptors" class="section level2">
<h2>Soluble Receptors</h2>
<ul>
<li>Etanercept - TNF receptor binding fusion protein
<ul>
<li>PASI (Psoriasis Area and Severity Index)</li>
<li>Sigmoid E<sub>max</sub>-model - EC50 2ug/ml</li>
</ul></li>
</ul>
</div>
<div id="monoclonal-antibodies" class="section level2">
<h2>Monoclonal antibodies</h2>
<ul>
<li>Table 12.2, Table 12.3, Table 12.3 - <strong>Approved therapeutic monoclonal antibodies</strong></li>
<li>Anti-TNF-<span class="math inline">\(\alpha\)</span> antibodies
<ul>
<li>infliximab (chimeric antibody)</li>
<li>fully humanized (adalimumab)</li>
<li>RA biomarker: ACR20 and EULAR improvement</li>
</ul></li>
<li>Therapeutic Antibodies in Oncology
<ul>
<li>Rituximab - anti-CD20 -&gt; B cells (ADCC, CDC, apoptosis)</li>
<li>PK of rituximab - nonlinear in multiple dose</li>
<li>CLL dose &gt; NHL dose: larger tumor burden and antigen sink</li>
<li>Bevacizumab: humanized IgG1 monoclonal antibody that binds and inhibits VEGF interaction with its receptor Flt-1 and KDR -&gt; angiogenesis.</li>
<li>Trastuzumab: targeting HER2 receptor</li>
</ul></li>
</ul>
<p>* The banner is inserted from the article <span class="citation">(Hansel et al. 2010)</span>.</p>
<div class="figure">
<img src="/assets/smallvsbio.jpg" alt="Comparison of PK" />
<p class="caption">Comparison of PK</p>
</div>
</div>
<div id="reference" class="section level2 unnumbered">
<h2>Reference</h2>
<div id="refs" class="references">
<div id="ref-Hansel_2010">
<p>Hansel, Trevor T., Harald Kropshofer, Thomas Singer, Jane A. Mitchell, and Andrew J. T. George. 2010. “The Safety and Side Effects of Monoclonal Antibodies.” <em>Nature Reviews Drug Discovery</em> 9 (4). Springer Nature: 325–38. doi:<a href="https://doi.org/10.1038/nrd3003">10.1038/nrd3003</a>.</p>
</div>
<div id="ref-biotechdrugs">
<p>Meibohm, Bernd. 2006. <em>Pharmacokinetics and Pharmacodynamics of Biotech Drugs : Principles and Case Studies in Drug Development</em>. Weinheim, Germany: Wiley-VCH.</p>
</div>
</div>
</div>
